Navigation Links
Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease
Date:10/8/2007

SAN DIEGO, Oct. 8 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that it has completed the patient enrollment of its Phase 3 study in fistulizing Crohn's disease. This pivotal, double-blind, placebo controlled study, FHAST1 (Fistula Healing with AST-120), has been designed to determine the efficacy and safety of oral AST-120 in 240 patients with Crohn's disease suffering from perianal fistulas. Initial data from the trial will be available in the first quarter of 2008.

"We are very pleased to have completed the enrollment in our FHAST1 pivotal trial evaluating AST-120 in a timely manner," stated Laurent Fischer, M.D., President and CEO of Ocera Therapeutics. "We would like to thank our investigators and patients in North America, Europe and Israel for their participation in the study."

Data from a double blind, placebo controlled Japanese study of AST-120 in fistulizing Crohn's disease sponsored by Kureha and presented at the Digestive Disease Week in May 2006 demonstrated that AST-120 significantly reduces draining fistulas compared to placebo.

"Up to one third of patients with Crohn's disease suffer from draining perianal fistulas, a chronic and debilitating condition that significantly affects their quality of life," said Professor Stephen Hanauer, M.D., Director of the Section of Gastroenterology and Nutrition at the University of Chicago and the Principal Investigator in the study. "Despite effective treatments, there is an unmet need for new and well-tolerated oral agents for patients with mild to moderate Crohn's disease who suffer from fistulas."

"We were pleased to participate in this Phase 3 trial evaluating the efficacy and safety of AST-120, a new oral treatment option, in fistulizing Crohn's disease," added Professor Simon Travis, M.D., Clinical Directo
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
5. Celsion Completes Enrollment in Phase I Liver Cancer Study
6. LANI completes Phase I in Japan and to commence Phase I in UK
7. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
(Date:7/9/2014)... Although feelings are personal and subjective, the ... that objectively represents emotions across different senses, situations ... Cornell University neuroscientist Adam Anderson. , "We discovered ... orbitofrontal cortex, an area of the brain associated ... which captures an individual,s subjective feeling," says Anderson, ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... that post-menopausal women who gain weight in adulthood are at ... irrespective of whether they are on hormone replacement therapy (HRT). ... have explored the relationship between breast cancer types and weight ... publication of the American Cancer Society. ,The effect ...
... officials in Tripura have announced that, they are taking preventive ... malaria from the past three months//. ,A ... also scheduled to visit Tripura to assess the situation and ... resistance. He also stated that almost 200 teams, consisting ...
... many youth under a spell. Recent figures have revealed the ... an increase of 400%, ever since the labour has come ... specialized services to remedy this menace, among children. Neil McKeganey, ... said: "These figures are shocking and they underline the reason ...
... is witness to an International Aids Candlelight Memorial which is ... very much a domestic problem and disassociating from it is ... estimated that nearly 2700 New Zealanders are suffering HIV. The ... people who had died of AIDS. But this time, it ...
... to end the medicos stir, the government has issued ... senior faculty members// who are supporting them. ... vacate hostels if they fail to return to work," ... step was taken after government issued advertisements for recruiting ...
... havoc with health, a new study has found that more ... suffers// from metabolic syndrome, a condition which predisposes people to ... per cent of the people in the age group of ... signified by combination of factors like high blood pressure, high ...
Cached Medicine News:Health News:Obese Women At Increased Risk Of Developing Breast Cancer 2Health News:Striking Students Asked to Vacate Hostels 2
... the heart of the Espion2 Electrophysiology system. ... aluminum chassis, real-time DSP, USB control, an ... differential amplifiers. The E2 connects to any ... over standard wi-fi Ethernet. The E2 includes ...
... breakthrough in visual field testing that's so ... FDT, the first visual field instrument that's ... to be used even in pre-test. Affordably ... clinical trials behind it to validate performance. ...
... Automatic Perimeter, a compact version of ... reputation, provides an accurate visual field ... and has function required for visual,field ... visual field very quickly. It ...
... AAA Endoprosthesis is an innovative device designed ... for patients with abdominal aortic aneurysms (AAA). ... bifurcated graft with an outer self-expanding Nitinol ... and material durability. The function of the ...
Medicine Products: